Hande Nur Eroğlu

Hande Nur Eroğlu

Auto-generated profile, based on publicly available information

Hande Nur Eroğlu

Süleyman Demirel University School of Medicine, Department of Public Health, Isparta, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
ÖÖÖzgür Önal
Özgür Önal
MKMurat Koçer
Murat Koçer
HEHande Nur Eroğlu
Hande Nur Eroğlu
SYServet Derya Yilmaz
Servet Derya Yilmaz
IEİsMet Eroğlu
İsMet Eroğlu
DKDilek Karadoğan
Dilek Karadoğan
Background/aim: This study aimed to investigate the effect of clinical and pathological indicators at the tone of the diagnosis on overall survival in patients recently diagnosed with non-small cell lung cancer. Materials and methods: The study population consisted of patients who were diagnosed at the Faculty of Medicine at Isparta Silleyman Demirel University Hospital between January 1, 2010 and December 31, 2017 and presented to the medical oncology outpatient clinic. Results: A total of 518 patients were evaluated, including 260 patients with squamous cell carcinoma, 207 patients with adenocarcinoma, 50 patients with non-small cell lung cancer-not otherwise specified, and 1 patient with large cell carcinoma. The average life expectancy was found to be 11.50 +/- 1.40 months in patients with squamous cell carcinoma, 12.60 +/- 1.59 months in patients with adenocarcinoma, and 8.70 +/- 1.87 months in the other patients. The estimated 5-year relative survival rate for non-small cell lung cancer was 8% (7% for men and 18% for women). In the multivariate analysis, sex being male (HR, 2.41; P < 0.001), a performance status >2 (HR, 1.70; P < 0.001), the stage of cancer (HR, 1.37; P = 0.045), the presence of bone or liver metastasis (HR, 1.44, P = 0.009, HR, 1.57; P = 0.016, respectively), and the patient not having received radiotherapy (HR, 3.25; P < 0.001) or chemotherapy (HR, 1.85; P = 0.001) were defined as statistically significant predictive factors that reduced the overall survival. Conclusions: In this study, sex, stage, performance status, the presence of liver or bone metastases, and treatment had an effect on overall survival.

1 May 2021 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
ÖÖÖzgür Önal
Özgür Önal
HEHande Nur Eroğlu
Hande Nur Eroğlu
FEFatma Yağmur Evcil
Fatma Yağmur Evcil
AKAhmet Nesimi Kişioğlu
Ahmet Nesimi Kişioğlu
EUErsin Uskun
Ersin Uskun
Objective: This study was planned to adapt the Vaccine Hesitancy Scale to Turkish and evaluate its validity and reliability. Material and Methods: This research was conducted methodologically. The sample of the study consisted of 317 individuals from the patient relatives in the waiting rooms, who have children between the ages 9-16, who applied to the Suleyman Demirel University Hospital policlinic in December 2019. A questionnaire developed by the researcher and the Vaccine Hesitancy Scale were used as data collection tools. Results: Explanatory factor analysis and confirmatory factor analysis methods were used to evaluate the validity and reliability of the Vaccine Hesitancy Scale. In the Vaccine Hesitancy Scale, the Kaiser-Mayer-Olkin coefficient was 0.897 and the Bartlett test’s chi-square value was 1319.67 and the result was significant (P <0.001). Considering the factor loads of the items, it varies between 0.608 and 0.845. As a result of the explanatory factor analysis, it was seen that the scale consists of two factors. This finding is consistent with the original form of the scale. The internal consistency coefficient of the scale was found to be 0.86. Conclusion: As a result of the validity and reliability analysis, the Vaccine Hesitancy Scale was found to be a valid and reliable scale for the Turkish society, which consists of 9 items and 2 sub-dimensions. Cite this article as: Önal Ö, Eroğlu HN, Evcil FY, Kişioğlu AN, Uskun E. Validity and reliability of Turkish version of the vaccine hesitancy scale “Turkish version of the vaccine hesitancy scale”. Turk Arch Pediatr 2021; 56(3): 230-5.

13 September 2021 in SDÜ Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
ÖÖÖzgür Önal
Özgür Önal
FEFatma Yağmur EVCİL
Fatma Yağmur EVCİL
HEHande Nur Eroğlu
Hande Nur Eroğlu
AKAhmet Ki̇şi̇oğlu
Ahmet Ki̇şi̇oğlu
Amaç Bu çalışma Üçüncü El Sigara Dumanı Hakkında Farkındalık Ölçeğini Türkçeye uyarlamak, geçerlik ve güvenirliğini değerlendirmek amacıyla yapılmıştır. Gereç ve Yöntem Metodolojik tipteki çalışma katılma kriterlerini karşılayan 315 kişi ile yapılmıştır. Veri toplama aracı olarak, araştırmacılar tarafından geliştirilen anket formu ve Üçüncü El Sigara Dumanı Hakkında Farkındalık Ölçeği kullanılmıştır. Güvenilirlik çalışmaları için madde analizi, Cronbach alfa katsayısı hesaplanmıştır. Ölçeğin geçerliliğini değerlendirmek için açıklayıcı ve doğrulayıcı faktör analizi yöntemleri uygulanmıştır. Bulgular Ölçeğin Kaiser-Meyer Olkin katsayısının 0.695 ve Bartlett testinin ki-kare değeri 661.77 ve sonucun anlamlı olduğu (p

1 January 2023 in Journal of Surgery and Medicine
Verified
Journal Article
Open access
PDF file
DODemircan Ozbalci
Demircan Ozbalci
EAEmine Guchan Alanoglu
Emine Guchan Alanoglu
KYKamuran Yuceer
Kamuran Yuceer
HEHande Nur Eroglu
Hande Nur Eroglu
Background/Aim: Hodgkin lymphoma (HL) is a lymphoproliferative malignancy associated with inflammation. Plateletcrit (PCT) is a mean platelet volume (MPV) and platelet count-derived marker that is useful for evaluating malignancies and inflammatory diseases. International Prognostic Score (IPS-7) and more recently, IPS-3, are two indices indicating the prognosis of patients; however, widespread and easy to interpret prognostic markers are still needed for HL evaluation. Very few studies evaluating the prognostic significance of platelet indices in HL have been published, so we aimed to show the relationship between PCT and other adverse prognostic factors in HL and evaluate whether PCT can be used as a prognostic marker in HL. Methods: After excluding patients with insufficient data, 75 patients diagnosed with HL and 150 healthy controls were retrospectively analyzed in this case-control study. Evaluation of relationship of PCT and adverse HL prognostic factors, such as age, gender, hemoglobin, leukocytes, lymphocytes (absolute value and percentage), albumin, Ann Arbor stage and B symptoms, IPS-3 and-7 prognostic scores and post-treatment relapse, and progression-free survival of the patients were studied. Results: Mean MPV values were significantly lower, mean platelet values were significantly higher inpatient group (all P<0.001). Patients with high sedimentation had significantly higher mean PCT than those without (P=0.031) and a moderately positive correlation between PCT and sedimentation were found (r=0.33, P<0.01). Mean PCT values after treatment significantly decreased compared to baseline levels (P<0.001). Conclusion: PCT may be useful as a prognostic marker in HL. Further studies were needed to evaluate the relationship between PCT and other prognostic factors, such as IPS-3 and -7. '+st+' Asisstant Prof. Dr. of Hematology Department Assitant Dr. of Internal medicine Specialist of Public Health Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1998 Apr;162:261-80. doi: 10.1111/j.1600-065x.1998.tb01447. x. PMID: 9602370. DOI: https://doi.org/10.1111/j.1600-065X.1998.tb01447.x Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991 Feb 9;337(8737):320-2. doi: 10.1016/0140-6736(91)90943-j. PMID: 1671232. DOI: https://doi.org/10.1016/0140-6736(91)90943-J Momotow J, Borchmann S, Eichenauer DA, Engert A, Sasse S. Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. J Clin Med. 2021 Mar 8;10(5):1125. doi: 10.3390/jcm10051125. PMID: 33800409; PMCID: PMC7962816. DOI: https://doi.org/10.3390/jcm10051125 Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest. 2012 Oct;122(10):3439-47. doi: 10.1172/JCI61245. Epub 2012 Oct 1. PMID: 23023715; PMCID: PMC3534167. DOI: https://doi.org/10.1172/JCI61245 von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin Lymphoma. Semin Hematol. 2016 Jul;53(3):180-5. doi: 10.1053/j.seminhematol.2016.05.010. Epub 2016 May 12. PMID: 27496309; PMCID: PMC5637390. DOI: https://doi.org/10.1053/j.seminhematol.2016.05.010 Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015 Sep;125(9):3384-91. doi: 10.1172/JCI80011. Epub 2015 Sep 1. PMID: 26325035; PMCID: PMC4588282. DOI: https://doi.org/10.1172/JCI80011 Moy RH, Younes A. Immune Checkpoint Inhibition in Hodgkin Lymphoma. Hemasphere. 2018 Feb 16;2(1):e20. doi: 10.1097/HS9.0000000000000020. PMID: 31723749; PMCID: PMC6745954. DOI: https://doi.org/10.1097/HS9.0000000000000020 Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015 Jul 30;126(5):582-8. doi: 10.1182/blood-2014-08-531582. Epub 2015 Jun 24. PMID: 26109205; PMCID: PMC4520875. DOI: https://doi.org/10.1182/blood-2014-08-531582 Ustaoglu G, Erdal E, Inanır M. Does periodontitis affect mean platelet volume (MPV) and plateletcrit (PCT) levels in healthy adults? Rev Assoc Med Bras (1992). 2020 May 15;66(2):133-8. doi: 10.1590/1806-9282.66.2.133. PMID: 32428146. DOI: https://doi.org/10.1590/1806-9282.66.2.133 Hur JY, Lee HY, Chang HJ, Choi CW, Kim DH, Eo WK. Preoperative plateletcrit is a Prognostic Biomarker for Survival in Patients with Non-Small Cell Lung Cancer. J Cancer. 2020 Feb 25;11(10):2800-7. doi: 10.7150/jca.41122. PMID: 32226498; PMCID: PMC7086273. DOI: https://doi.org/10.7150/jca.41122 Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7. PMID: 26343802; PMCID: PMC4881845. DOI: https://doi.org/10.1111/bjh.13634 Karagoz B, Sucullu I, Sayan O, Bilgi O, Tuncel T, Filiz A, et al. Platelet indices in patients with colorectal cancer. Open Medicine. 2010;5(3): 365-8. doi: 10.2478/s11536-009-0077-7 DOI: https://doi.org/10.2478/s11536-009-0077-7 Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019 Apr 17; 2019:9213074. doi: 10.1155/2019/9213074. PMID: 31148950; PMCID: PMC6501263. DOI: https://doi.org/10.1155/2019/9213074 Kumagai S, Tokuno J, Ueda Y, Marumo S, Shoji T, Nishimura T, et al. Prognostic significance of preoperative mean platelet volume in resected non-small-cell lung cancer. Mol Clin Oncol. 2015 Jan;3(1):197-201. doi: 10.3892/mco.2014.436. Epub 2014 Oct 6. PMID: 25469294; PMCID: PMC4251106. DOI: https://doi.org/10.3892/mco.2014.436 Shen WJ, Fu S, Li N, Li LL, Cao ZG, Li C, et al. Decreased Mean Platelet Volume is Associated with Cervical Cancer Development. Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1769-72. doi: 10.22034/APJCP.2017.18.7.1769. PMID: 28749103; PMCID: PMC5648377. Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget. 2018 Apr 20;9(30):21190-200. doi: 10.18632/oncotarget.25002. PMID: 29765530; PMCID: PMC5940371. DOI: https://doi.org/10.18632/oncotarget.25002 Plantureux L, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. Cancers (Basel). 2018 Nov 14;10(11):441. doi: 10.3390/cancers10110441. PMID: 30441823; PMCID: PMC6266827. DOI: https://doi.org/10.3390/cancers10110441 Randi ML, Rossi C, Barbone E, Pietrogrande F, Girolami A. Incidence of thrombocytosis in lymphomas. Leuk Lymphoma. 1992 May;7(1-2):139-41. doi: 10.3109/10428199209053614. PMID: 1472925. DOI: https://doi.org/10.3109/10428199209053614 Zhu X, Cao Y, Lu P, Kang Y, Lin Z, Hao T, et al. Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer. Sci Rep. 2018 Aug 7;8(1):11814. doi: 10.1038/s41598-018-29293-x. PMID: 30087357; PMCID: PMC6081379. DOI: https://doi.org/10.1038/s41598-018-29293-x Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005 Aug 1;23(22):5052-60. doi: 10.1200/JCO.2005.11.080. Epub 2005 Jun 13. PMID: 15955904. DOI: https://doi.org/10.1200/JCO.2005.11.080 Tao Y, He X, Qin Y, Liu P, Zhou S, Yang J, et al. Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma. Leuk Lymphoma. 2021 Jul 23:1-11. doi: 10.1080/10428194.2021.1953015. Epub ahead of print. PMID: 34296652. DOI: https://doi.org/10.1080/10428194.2021.1953015 Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early-stage classical Hodgkin lymphoma. Br J Haematol. 2018 Feb;180(4):545-9. doi: 10.1111/bjh.15054. Epub 2017 Dec 21. PMID: 29271057. DOI: https://doi.org/10.1111/bjh.15054 Copyright (c) 2023 Demircan Ozbalci, Emine Guchan Alanoglu, Kamuran Yuceer, Hande Nur Eroglu This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

1 June 2023 in Flora the Journal of Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
EUErsin Uskun
Ersin Uskun
MDMurat Dündar
Murat Dündar
HEHande Nur Eroğlu
Hande Nur Eroğlu
MDMustafa Develi
Mustafa Develi
SYServet Derya Yılmaz
Servet Derya Yılmaz
AKAhmet Nesimi Kişioğlu
Ahmet Nesimi Kişioğlu